BLOG

Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.